Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Life crawled date : 2022 - 10 - 25 save search
Mondelēz International Doubles Down on Cocoa Life Program with Total Investment of $1 Billion by 2030; Calls for More Sector-Wide Action
Published: 2022-10-25 (Crawled : 21:00) - globenewswire.com
MDLZ | $70.76 1.94% 1.91% 16M
|
Consumer Non-Durables
|
| O: 0.89%
H: 1.17%
C: 0.1%
life program international
Chubb Reports Third Quarter Net Income Per Share of $1.94 Versus $4.18 Prior Year, and Core Operating Income Per Share of $3.17, Up 20.1%; Consolidated Net Premiums Written Up 14.4%, or 17.3% in Constant Dollars, with P&C Up 11.2%; Life Division Premiums More Than Doubled with the Acquisition of Cigna's Asia Business; P&C Combined Ratio was 93.1%, with Catastrophe Losses of $1.2 Billion, Including $975 Million from Hurricane Ian, and 87.5% Year-to-Date
Published: 2022-10-25 (Crawled : 21:00) - prnewswire.com
CB | News | $249.88 -0.64% 0.0% 1.9M
|
Finance
|
| O: 6.09%
H: 0.15%
C: -4.47%
acquisition life
Koneksa Announces Clinical Pipeline of Validated Digital Biomarkers to Accelerate Life Sciences Research
Published: 2022-10-25 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.03%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.83%
H: 0.0%
C: 0.0%
sciences research life biomarkers
ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of Two U.S. Patents
Published: 2022-10-25 (Crawled : 13:20) - biospace.com/
NDRA | $0.248 -0.88% -0.89% 37K
|
Health Technology
|
| O: 0.38%
H: 6.59%
C: 3.54%
taeus sciences system life
STEMTECH CORPORATION ANNOUNCES LIFE FACTOR RESEARCH BECOMES PART OF STEMTECH
Published: 2022-10-25 (Crawled : 13:00) - globenewswire.com
STEK | $0.0614 -62.89% 81K
|
n/a
|
| O: -9.17%
H: 22.26%
C: 9.68%
research life corporation
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
Published: 2022-10-25 (Crawled : 11:00) - globenewswire.com
ATAI | $1.97 5.35% 5.08% 1.2M
|
Manufacturing
|
| O: 3.81%
H: 2.95%
C: 0.67%
pcn-101 sciences life trial depression phase 2b
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.